Aligos reports Q3 2026 results, B-SUPREME trial on track for late Q3 2027 data
Enrollment is complete in the Phase 2 hepatitis B study of pevifoscorvir sodium, and Aligos says its cash runway extends into early 2027.
Aligos Therapeutics reported business updates and third quarter 2026 financial results on November 6, 2026. Chief Executive Lawrence Blatt said the company continued to advance its Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for a topline data readout in late Q3 2027, with enrollment complete and 70 participants having completed 48 weeks of treatment.1
The study, registered as NCT06963710, has completed enrollment with 131 participants in the HBeAg+ cohort (Part 1a) and 114 participants in the HBeAg- cohort (Part 2a).1 Topline data for both cohorts are expected in late Q3 2027.1
On the company's antisense oligonucleotide program, Blatt noted ALG-170675 is currently in a Phase 1 study in China with partner Amoytop.1 Aligos said Amoytop is funding development costs in China and holds rights in Greater China, while Aligos may use data from those studies for regulatory filings elsewhere, with each party responsible for its own development costs under the agreement.1
On finances, Aligos said cash, cash equivalents and investments were $31.1 million as of September 30, 2026, down from $77.8 million at the end of 2025.1 The company said this cash position is expected to fund planned operations into the first quarter of 2027.1 Net loss for the quarter was $21.9 million, or $(2.09) per share, compared with a net loss of $31.5 million, or $(3.04) per share, in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.